Literature DB >> 11679966

TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells.

B Schnabl1, C A Bradham, B L Bennett, A M Manning, B Stefanovic, D A Brenner.   

Abstract

After liver injury, hepatic stellate cells (HSCs) undergo a process of activation with expression of smooth muscle alpha-actin (alpha-SMA), an increased proliferation rate, and a dramatic increase in synthesis of type I collagen. The intracellular signaling mechanisms of activation and perpetuation of the activated phenotype in HSCs are largely unknown. In this study the role of the stress-activated protein kinases, c-Jun N-terminal kinase (JNK) and p38, were evaluated in primary cultures of rat HSCs. The effect of JNK was assessed by using an adenovirus expressing a dominant negative form of transforming growth factor beta (TGF-beta)-activated kinase 1 (TAK1) (Ad5dnTAK1) and a new selective pharmacologic inhibitor SP600125. The effect of p38 was assessed with the selective pharmacologic inhibitor SB203580. These kinases were inhibited starting either in quiescent HSCs (culture day 1) or in activated HSCs (culture day 5). Although blocking TAK1/JNK and p38 decreased the expression of alpha-SMA protein in early stages of HSC activation, no effect was observed when TAK1/JNK or p38 were inhibited in activated HSCs. JNK inhibition increased and p38 inhibition decreased collagen alpha1(I) mRNA level as measured by RNase protection assays, with maximal effects observed in early stages of HSC activation. Furthermore, TAK1/JNK inhibition decreased HSC proliferation, whereas p38 inhibition led to an increased proliferation rate of HSCs, independently of its activation status. These results show novel roles for the TAK1/JNK pathway and p38 during HSC activation in culture. Despite similar activators of TAK1/JNK and p38, their functions in HSCs are distinct and opposed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679966     DOI: 10.1053/jhep.2001.28790

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  35 in total

Review 1.  Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies.

Authors:  Jing-Ting Li; Zhang-Xiu Liao; Jie Ping; Dan Xu; Hui Wang
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

2.  Transforming growth factor beta-activated kinase 1 is a key mediator of ovine follicle-stimulating hormone beta-subunit expression.

Authors:  Nedal Safwat; Jun Ninomiya-Tsuji; A Jesse Gore; William L Miller
Journal:  Endocrinology       Date:  2005-08-04       Impact factor: 4.736

3.  Ca²⁺/calmodulin-dependent protein kinase II mediates platelet-derived growth factor-induced human hepatic stellate cell proliferation.

Authors:  An Ping; Tian Yihao; Dai Jingxing; Chen Minkai; Luo Hesheng
Journal:  Dig Dis Sci       Date:  2012-01-04       Impact factor: 3.199

4.  Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury.

Authors:  Katsunori Yoshida; Koichi Matsuzaki; Shigeo Mori; Yoshiya Tahashi; Hideo Yamagata; Fukiko Furukawa; Toshihito Seki; Mikio Nishizawa; Junichi Fujisawa; Kazuichi Okazaki
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

Review 5.  A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches.

Authors:  Ekihiro Seki; David A Brenner; Michael Karin
Journal:  Gastroenterology       Date:  2012-06-13       Impact factor: 22.682

6.  NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis.

Authors:  Ramon Bataller; Robert F Schwabe; Youkyung H Choi; Liu Yang; Yong Han Paik; Jeffrey Lindquist; Ting Qian; Robert Schoonhoven; Curt H Hagedorn; John J Lemasters; David A Brenner
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

7.  The specificities of protein kinase inhibitors: an update.

Authors:  Jenny Bain; Hilary McLauchlan; Matthew Elliott; Philip Cohen
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

8.  Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis.

Authors:  Sayaka Inokuchi; Tomonori Aoyama; Kouichi Miura; Christoph H Osterreicher; Yuzo Kodama; Katsumi Miyai; Shizuo Akira; David A Brenner; Ekihiro Seki
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-18       Impact factor: 11.205

9.  Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition.

Authors:  Johannes Kluwe; Jean-Philippe Pradere; Geum-Youn Gwak; Ali Mencin; Samuele De Minicis; Christoph H Osterreicher; Jordi Colmenero; Ramon Bataller; Robert F Schwabe
Journal:  Gastroenterology       Date:  2009-09-24       Impact factor: 22.682

Review 10.  TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis.

Authors:  Fengyun Xu; Changwei Liu; Dandan Zhou; Lei Zhang
Journal:  J Histochem Cytochem       Date:  2016-01-08       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.